Based on the PPI network and KEGG enrichment analysis, a set of ten hub genes (GAPDH, AKT1, CASP3, GSK3B, EGFR, STAT3, ESR1, MMP9, NFκB1, and MTOR) and five potential targets (BACE1, CDK5, ADAM17, CDK5R1, and MME) have been recognized as having involvement in the neuroprotective effects on AD-associated with MS. The gene discussed is ADAM17; the disease is myeloid sarcoma.